Andre Goy, MD, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL)
Andre Goy, MD, chairman, director and chief of Lymphoma at John Theurer Cancer Center, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL).
Goy says this is the first time that lenalidomide is approved in a lymphoma and is only the second drug approved for relapsed or refractory MCL. Lenalidomide was recently approved for multiple myeloma.
There was evidence that the drug showed activity in lymphoma recently, Goy says, but it took time to generate data to prove that to be true.
A phase II trial focused on 134 patients who had failed standard of care for relapsed or refractory MCL, Goy says. In the study, 29% of patients responded to treatment while about 8% demonstrated complete response. The duration of response for these patients was close to 16 months, Goy says, demonstrating an improvement over chemotherapy.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More